UROSCREEN: a home-based first-void URine One-step triage option for cervical cancer SCREENing.

Cervical cancer remains a significant problem worldwide, in Belgium, yearly over 200 women die from this disease. Almost all cervical cancer cases are caused by an infection with high risk (HR) types of the Human Papillomavirus (HPV). Traditional screening programs based on cervical smear taking (pap smear) detecting abnormal cells face numerous limitations, urging the need for alternative screening approaches. Detection of highly sensitive HR-HPV DNA in combination with more specific biomarkers such as methylation of host cell genes offer the opportunity to be detected in self-collected samples, like first-void urine. Therefore, we aim to demonstrate the clinical accuracy of HPV testing in first-void urine (WP2), in combination with triage markers (WP3). Followed by a population based pilot study to evaluate the performance of this novel screen and triage algorithm compared to self- and clinician-collected samples (WP4). And hereto offer a highly-accepted screening solution to women, especially benefitting hard-to-reach populations. And by means of this, decreasing the burden of cervical cancer associated disease and mortality.

Keywords:HPV, SCREENING, CERVICAL CANCER, BIOMARKERS

Disciplines:Public health sciences not elsewhere classified, Molecular diagnostics, Infectious diseases, Cancer diagnosis

Project type:Collaboration project